Metabolic
Unlocking Your Body’s Natural Weight Loss System That Works Like Wegovy, Ozempic and Mounjaro
Recent drugs like Wegovy, Ozempic, and Mounjaro represent breakthroughs in metabolic disease treatment, offering new hope for managing obesity and diabetes. However, their use raises questions about long-term effects and suitability for certain groups, underscoring the importance of a healthy lifestyle.
Wegovy, Ozempic, and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news. They target regulatory pathways involved in both obesity and diabetes and are widely considered breakthroughs for weight loss and blood sugar control.
But do these drugs point toward a root cause of metabolic disease? What inspired their development in the first place?
It turns out your body produces natural versions of these drugs – also known as incretin hormones – in your gut. It may not be surprising that nutrients in food help regulate these hormones. But it may intrigue you to know that the trillions of microbes in your gut are key for orchestrating this process.
I am a gastroenterologist at the
Prior to modern processed foods, metabolic regulatory pathways were under the direction of a diverse healthy gut microbiome that used these hormones to naturally regulate your metabolism and appetite. However, food processing, aimed at improving shelf stability and enhancing taste, removes the bioactive molecules like fiber and polyphenols that help regulate this system.
Removal of these key food components and the resulting decrease in gut microbiome diversity may be an important factor contributing to the rise in obesity and diabetes.
A Short Track to Metabolic Health
Wegovy and Ozempic reinvigorate the colonic brake downstream of food and microbes with molecules similar to GLP-1. Researchers have demonstrated their effectiveness at weight loss and blood sugar control.
Mounjaro has gone a step further and combined GLP-1 with a second hormone analog derived from the upper gut called GIP, and studies are showing this combination therapy to be even more effective at promoting weight loss than GLP-1-only therapies like Wegovy and Ozempic.
These drugs complement other measures like gastric bypass surgery that are used in the most extreme cases of metabolic disease. These surgeries may in part work much like Wegovy and Ozempic by bypassing digestion in segments of the gastrointestinal tract and bathing your gut microbes in less digested food. This awakens the microbes to stimulate your gut cells to produce GLP-1 and PYY, effectively regulating appetite and metabolism.
Many patients have seen significant improvements to not only their weight and blood glucose but also reductions in important cardiovascular outcomes like strokes and heart attacks. Medical guidelines support the use of new incretin-based medications like Wegovy, Ozempic and Mounjaro to manage the interrelated metabolic conditions of diabetes, obesity and